Is Epigral a Good Buy After Its Q1 FY27 Results?
- September 10, 2026
- Posted by: Harsh Piplani
- Category: Market
Epigral share price around Rs 1,147. 36.6% below 52-week high of Rs 1,809. Q1 FY27 revenue Rs 709 crore, up 15.4% YoY. PAT Rs 100 crore, down 37.9%. PE 18x.
Quick Answer
Epigral’s Q1 FY27 results were mixed, with revenue at Rs 709 crore but PAT falling 38% to Rs 100 crore. The Epigral share price near Rs 1,147 has not escaped this pressure, and the profit decline is the key data point investors should weigh before deciding whether Epigral is a good buy right now.
The Epigral share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Epigral is formerly Meghmani Finechem, a leading integrated manufacturer of chlor-alkali and specialty chemicals, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.
Revenue for the quarter came in at Rs 709 crore, up 15.4% year on year, while profit after tax came in at Rs 100 crore, down 37.9% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Epigral share price from here.
This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Epigral share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.
Click Here – Get Free Investment Predictions
Epigral Q1 FY27 Financial Highlights
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 709 crore | Rs 615 crore | 15.4% |
| EBITDA | Rs 183 crore | Rs 172 crore | 6.8% |
| Operating Margin | 26.1% | 28.3% | NA |
| Profit Before Tax | Rs 134 crore | Rs 107 crore | 25.0% |
| Net Profit / (Loss) | Rs 100 crore | Rs 161 crore | -37.9% |
Epigral Q1 FY27 Performance Analysis
Check Epigral Fundamentals on Univest Screener
Revenue growth of 15.4% for the quarter came from steady demand across the company’s core business, keeping the topline trend intact for the chlor-alkali and speciality chemicals manufacturing sector.
Profitability is where the quarter disappointed. PAT fell 38% year on year to Rs 100 crore even as revenue grew, which points to margin or cost pressure that management will need to address. This gap between top-line and bottom-line performance is the key thing weighing on the Epigral share price this quarter.
On a sequential basis, revenue moved down 3.6% sequentially from Rs 736 crore in the March 2026 quarter and net profit moved up 23.2% sequentially from Rs 81 crore in the prior quarter, giving a fuller picture of the trend behind the Epigral share price than the year on year comparison alone.
Key Business Factors in Q1 FY27
Revenue Trend
Epigral’s revenue grew 15.4% year on year this quarter, taking the quarterly base to Rs 709 crore in a chlor-alkali and speciality chemicals manufacturing business that remains sensitive to demand and pricing cycles that ultimately feed through to the Epigral share price.
Margin Movement
EBITDA rose 6.8% to Rs 183 crore, and operating margin moved to 26.1% from 28.3% a year earlier, a sign that cost control or pricing held up during the quarter.
Balance Sheet Position
Epigral carries a low debt-to-equity ratio of 0.26, giving it a conservative balance sheet heading into the rest of FY27.
Valuation Context
The stock trades at a PE of 18.5x, below the industry average of 37.5x, which is worth factoring into any read of whether the Epigral share price is expensive or reasonably priced.
Dividend Details
No interim dividend was declared alongside Epigral’s Q1 FY27 results. The stock currently carries a trailing dividend yield of 0.43%, based on dividends paid over the last year. Investors tracking the Epigral share price for income should watch the company’s announcements around its next annual results for any dividend decision.
Epigral Share Price Outlook for FY27
The key question for the rest of FY27 is whether Epigral can arrest the margin pressure seen this quarter. Revenue growth alone will not be enough to support the Epigral share price if profitability keeps slipping, so investors should watch the next couple of quarters for signs of a turnaround in the bottom line.
A stabilising or improving margin trend in the next result would be the clearest signal that this quarter’s profit decline was a temporary setback rather than the start of a longer slide for the Epigral share price.
Epigral Stock Performance
Download the Univest iOS App or Univest Android App to track Epigral’s live share price and get daily stock updates.
The Epigral share price was trading around Rs 1,147 as results season played out in late August 2026, roughly 36.6% below its 52-week high of Rs 1,809 and well above its 52-week low of Rs 806. Promoter holding stood at 68.8% as of the June 2026 quarter.
The Epigral share price has likely already absorbed some of this quarter’s disappointment, but further downside is possible if the next results confirm the same trend rather than a one-off. On profitability ratios, the company reports a return on equity of 14.94% and a book value of around Rs 515 per share, both useful reference points when judging whether the current price is reasonable.
Key Risks
Profitability Risk
The quarter’s profit trend is the clearest risk here. Until Epigral shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results.
Sector and Demand Risk
As a chlor-alkali and speciality chemicals manufacturing business, Epigral’s results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Epigral share price well before the next result.
Execution Risk
Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.
Conclusion
Epigral’s Q1 FY27 results show a business still growing its top line but losing ground on profitability, with PAT down 38% to Rs 100 crore even as revenue rose. The Epigral share price reflects a stock in wait-and-watch mode, and it is not an obvious buy purely on this quarter’s numbers until the margin trend turns around.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Epigral Q1 FY27 Results
What were Epigral’s Q1 FY27 results?
Ans. Epigral reported Q1 FY27 revenue of Rs 709 crore, up 15.4% year on year, and PAT of Rs 100 crore, down 37.9% year on year.
Is Epigral a good buy after its Q1 FY27 results?
Ans. Epigral’s profitability came under pressure this quarter, which makes this a stock to watch rather than an obvious buy purely on this result. Investors should form their own view based on their own risk appetite and time horizon.
What is the Epigral share price today?
Ans. The Epigral share price was trading around Rs 1,147 in late August 2026, about 36.6% below its 52-week high of Rs 1,809 and well above its 52-week low of Rs 806.
What is Epigral’s revenue and profit for Q1 FY27?
Ans. Epigral reported revenue of Rs 709 crore and a net profit of Rs 100 crore for the quarter ended June 30, 2026.
Did Epigral declare a dividend with its Q1 FY27 results?
Ans. No interim dividend was declared alongside Epigral’s Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.
What is Epigral’s PE ratio and is it expensive?
Ans. The Epigral share price trades at a trailing PE of 18.5x, against an industry average of 37.5x. Investors should compare this with the company’s growth rate before judging value.
What are the key risks for Epigral investors right now?
Ans. The quarter’s profit trend is the clearest risk here. Until Epigral shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results. Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.
What is Epigral’s promoter shareholding?
Ans. Promoter holding in Epigral stood at 68.8% as of the June 2026 quarter.
